210 related articles for article (PubMed ID: 15246632)
1. Pertussis vaccination strategies for neonates--an exploratory cost-effectiveness analysis.
Scuffham PA; McIntyre PB
Vaccine; 2004 Jul; 22(21-22):2953-64. PubMed ID: 15246632
[TBL] [Abstract][Full Text] [Related]
2. Pertussis in adolescents and adults: should we vaccinate?
Lee GM; Lebaron C; Murphy TV; Lett S; Schauer S; Lieu TA
Pediatrics; 2005 Jun; 115(6):1675-84. PubMed ID: 15930232
[TBL] [Abstract][Full Text] [Related]
3. Pertussis in infants: preventing deaths and hospitalisations in the very young.
Wood N; Quinn HE; McIntyre P; Elliott E
J Paediatr Child Health; 2008 Apr; 44(4):161-5. PubMed ID: 18377367
[TBL] [Abstract][Full Text] [Related]
4. Economic evaluation of an extended acellular pertussis vaccine programme for adolescents in Ontario, Canada.
Iskedjian M; Walker JH; Hemels ME
Vaccine; 2004 Oct; 22(31-32):4215-27. PubMed ID: 15474711
[TBL] [Abstract][Full Text] [Related]
5. Cost effectiveness of pertussis vaccination in adults.
Lee GM; Murphy TV; Lett S; Cortese MM; Kretsinger K; Schauer S; Lieu TA
Am J Prev Med; 2007 Mar; 32(3):186-193. PubMed ID: 17296470
[TBL] [Abstract][Full Text] [Related]
6. The cost of epidemiological transition: a study of a decrease in pertussis vaccination coverage.
Girard DZ
Health Policy; 2005 Nov; 74(3):287-303. PubMed ID: 15951048
[TBL] [Abstract][Full Text] [Related]
7. Economic impact of the introduction of an acellular pertussis vaccine in Canada: a 6-year analysis.
Iskedjian M; De Serres G; Einarson TR; Walker JH
Vaccine; 2010 Jan; 28(3):714-23. PubMed ID: 19895923
[TBL] [Abstract][Full Text] [Related]
8. Economic analysis of pertussis illness in the Dutch population: implications for current and future vaccination strategies.
de Greeff SC; Lugnér AK; van den Heuvel DM; Mooi FR; de Melker HE
Vaccine; 2009 Mar; 27(13):1932-7. PubMed ID: 19368774
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of various pertussis vaccination strategies primarily aimed at protecting infants in the Netherlands.
Westra TA; de Vries R; Tamminga JJ; Sauboin CJ; Postma MJ
Clin Ther; 2010 Aug; 32(8):1479-95. PubMed ID: 20728761
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of a pertussis vaccination programme for Japan considering intergenerational infection.
Itatani T; Shimizu S; Iwasa M; Ohkusa Y; Hayakawa K
Vaccine; 2013 Jun; 31(27):2891-7. PubMed ID: 23570987
[TBL] [Abstract][Full Text] [Related]
11. Using computer simulations to compare pertussis vaccination strategies in Australia.
Hethcote HW; Horby P; McIntyre P
Vaccine; 2004 Jun; 22(17-18):2181-91. PubMed ID: 15149775
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness and potential impact of rotavirus vaccination in the United States.
Widdowson MA; Meltzer MI; Zhang X; Bresee JS; Parashar UD; Glass RI
Pediatrics; 2007 Apr; 119(4):684-97. PubMed ID: 17403839
[TBL] [Abstract][Full Text] [Related]
13. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.
Bisgard KM; Rhodes P; Connelly BL; Bi D; Hahn C; Patrick S; Glodé MP; Ehresmann KR;
Pediatrics; 2005 Aug; 116(2):e285-94. PubMed ID: 16061582
[TBL] [Abstract][Full Text] [Related]
14. Rotavirus vaccination for Hong Kong children: an economic evaluation from the Hong Kong Government perspective.
Ho AM; Nelson EA; Walker DG
Arch Dis Child; 2008 Jan; 93(1):52-8. PubMed ID: 17855438
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of targeted vaccination to protect new-borns against pertussis: comparing neonatal, maternal, and cocooning vaccination strategies.
Lugnér AK; van der Maas N; van Boven M; Mooi FR; de Melker HE
Vaccine; 2013 Nov; 31(46):5392-7. PubMed ID: 24075918
[TBL] [Abstract][Full Text] [Related]
16. Vaccine Timeliness: A Cost Analysis of the Potential Implications of Delayed Pertussis Vaccination in the US.
Curran D; Terlinden A; Poirrier JE; Masseria C; Krishnarajah G
Pediatr Infect Dis J; 2016 May; 35(5):542-7. PubMed ID: 26835971
[TBL] [Abstract][Full Text] [Related]
17. Use of models to identify cost-effective interventions: pertussis vaccination for pediatric health care workers.
Greer AL; Fisman DN
Pediatrics; 2011 Sep; 128(3):e591-9. PubMed ID: 21844056
[TBL] [Abstract][Full Text] [Related]
18. Pertussis vaccine--an analysis of benefits, risks and costs.
Koplan JP; Schoenbaum SC; Weinstein MC; Fraser DW
N Engl J Med; 1979 Oct; 301(17):906-11. PubMed ID: 39253
[TBL] [Abstract][Full Text] [Related]
19. Economic evaluation of Haemophilus influenzae type b vaccination in Moscow, Russian Federation.
Platonov AE; Griffiths UK; Voeykova MV; Platonova OV; Shakhanina IL; Chistyakova GG; Robertson SE;
Vaccine; 2006 Mar; 24(13):2367-76. PubMed ID: 16413949
[TBL] [Abstract][Full Text] [Related]
20. Pregnancy dose Tdap and postpartum cocooning to prevent infant pertussis: a decision analysis.
Terranella A; Asay GR; Messonnier ML; Clark TA; Liang JL
Pediatrics; 2013 Jun; 131(6):e1748-56. PubMed ID: 23713104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
